# IDeate-Lung02: HCP commentary report

> 159 verified statements (71 from clinicians verified by NPI or staff page) from 30 commentary sources · 8 findings · updated Oct 30, 2026

## Report

- Trial: A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
- NCT ID: NCT06203210
- Registry: https://clinicaltrials.gov/study/NCT06203210
- Sponsor: Daiichi Sankyo
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: ifinatamab deruxtecan
- Indication: relapsed small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-30
- Last checked: 2026-10-30
- Release hash: 34b28c7ed1dfb77cb67a8a741847ef4109dfd80d40c1b84bbee8d3dd4db0cabc

## Counts

- HCP commentary sources screened: 64
- Sources cited by verified statements: 32
- Verified statements: 159
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 71
- Findings: 8
- Named people in screened sources (unnamed speakers and accounts not counted): 27
- Voices cited: 25
- Cited voices identity-verified: 20
- Organisational or shared accounts (not counted as people): 7

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on IDeate-Lung02 in the sources reviewed for this edition leads to one open question: What survival, durability, pulmonary-safety and delivery advantages would justify I-DXd at relapse, and for which prior-treatment groups? Its leading findings: (1) fatal ILD makes tolerability a consequential, disputed judgment. (2) withdrawal shifts attention to randomized evidence without determining the program's outcome. (3) the relevant comparator depends on available therapy, prior exposure and delivery burden. 5 more findings follow. 64 sources screened, 32 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

What survival, durability, pulmonary-safety and delivery advantages would justify I-DXd at relapse, and for which prior-treatment groups?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Fatal ILD makes tolerability a consequential, disputed judgment
- F2. Withdrawal shifts attention to randomized evidence without determining the program's outcome
- F3. The relevant comparator depends on available therapy, prior exposure and delivery burden
- F4. Dose reduction is proposed, but the perceived efficacy–toxicity window is narrow
- F5. Early systemic and CNS activity motivates development, with explicit limits on evidence maturity
- F6. Relapse work-up and disease distribution can redirect the treatment decision
- F7. B7-H3 optimism and proposed immune strategies extend beyond the I-DXd filing, without transferable proof
- F8. The access gap drives early trial conversations and repeated patient-support needs

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 29 | 14 | 10 | 12 | recorded | 5 |
| F2 | 37 | 22 | 19 | 15 | none recorded | 3 |
| F3 | 17 | 8 | 4 | 7 | recorded | 4 |
| F4 | 11 | 8 | 4 | 4 | recorded | 4 |
| F5 | 28 | 16 | 11 | 12 | none recorded | 3 |
| F6 | 12 | 12 | 2 | 6 | none recorded | 3 |
| F7 | 33 | 11 | 7 | 8 | recorded | 4 |
| F8 | 17 | 11 | 7 | 9 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 18 | 2 | 0 | 1 | 8 | 33 | 6 | 9 posts and articles, 1 podcast or video | yes |
| F2 | 16 | 3 | 0 | 1 | 17 | 42 | 6 | 17 posts and articles, 1 publication, 1 registry | yes |
| F3 | 6 | 0 | 0 | 5 | 6 | 20 | 2 | 4 posts and articles | yes |
| F4 | 5 | 0 | 0 | 1 | 5 | 12 | 1 | 2 posts and articles, 1 podcast or video, 1 publication | yes |
| F5 | 15 | 1 | 1 | 2 | 9 | 34 | 4 | 10 posts and articles, 1 podcast or video | yes |
| F6 | 5 | 4 | 0 | 0 | 3 | 12 | 4 | 1 post or article, 1 publication | yes |
| F7 | 18 | 2 | 0 | 4 | 9 | 36 | 2 | 5 posts and articles, 2 podcasts and video | yes |
| F8 | 11 | 2 | 1 | 0 | 3 | 19 | 0 | 6 posts and articles, 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Overall Survival (OS): F2 (7 shared claims), F3 (1 shared claims), F5 (3 shared claims), F7 (1 shared claims)
- Secondary endpoints: F2 (6 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (6 shared claims), F8 (1 shared claims)
- Population and setting: F2 (1 shared claims), F3 (4 shared claims), F5 (7 shared claims), F6 (5 shared claims), F7 (1 shared claims)
- The comparison: F3 (9 shared claims), F5 (2 shared claims), F6 (1 shared claims), F7 (1 shared claims)
- Safety and tolerability: F1 (18 shared claims), F4 (8 shared claims), F5 (4 shared claims), F7 (2 shared claims)
- Design and conduct: F1 (3 shared claims), F2 (9 shared claims), F4 (1 shared claims), F5 (4 shared claims), F7 (1 shared claims), F8 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 10 sections | Paid |
| Verified statements with short source quotes and links | 159 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 32 | Counts free |
| Speaker attribution for cited voices | 25 | Paid |

## Trial aspects

12 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival (OS) | discussed | 9 | 6 |
| Secondary endpoints | discussed | 13 | 13 |
| Population and setting | discussed | 16 | 5 |
| The comparison | discussed | 12 | 5 |
| Safety and tolerability | discussed | 26 | 12 |
| Design and conduct | discussed | 16 | 13 |
| Accelerated-approval sufficiency, withdrawal and a possible future filing | discussed | 32 | 13 |
| Dose selection and the perceived therapeutic window | discussed | 9 | 3 |
| CNS assessment, resistance work-up and localized relapse choices | discussed | 12 | 2 |
| Imdelltra exposure, delivery burden and the changing relapse benchmark | discussed | 15 | 5 |
| B7-H3 rationale, alternative ADCs, immune-instruction proposals and international applicability | discussed | 21 | 7 |
| Patient access, trial referral and adverse-event communication | discussed | 20 | 8 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 55 | 26 |
| Bluesky threads | 5 | 1 |
| YouTube | 2 | 1 |
| LinkedIn posts | 1 | 1 |
| Podcasts | 1 | 1 |
| Publications (primary source, cited for context) | not screened | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2024-01-12 to 2026-10-24
- Cited window: 2024-03-27 to 2026-10-08
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
- Registry: NCT06203210 (https://clinicaltrials.gov/study/NCT06203210)
- Study IDs: DS7300-188 · 2023-509628-16-00 (EU CT) · 2031230631 (jRCT)
- Sponsor: Daiichi Sankyo
- Collaborators: Merck Sharp & Dohme LLC
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 540 (estimated)
- Start: 2024-05-21 (actual)
- Primary completion: 2028-01-30 (estimated)
- Primary endpoint: Overall Survival (OS) (From the date of randomization to the date of death due to any cause, up to approximately 3.7 years)
- Intervention: Ifinatamab deruxtecan (drug)
- Intervention: Topotecan (drug)
- Intervention: Amrubicin (drug)
- Intervention: Lurbinectedin (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on reduced monitoring requirements and community feasibility of an alternative treatment for relapsed small cell lung cancer.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 86 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are not representative of all HCP discussion. Unnamed references, differently rendered trial names and incompletely evaluated passages may leave relevant views absent.
- The material mixes physician commentary with organizational, company-relay and public-account statements. Uncertain clinical roles and unnamed authors limit conclusions about clinician consensus.
- Audio/video versions of one episode, duplicated posts and reposts should not be counted as independent agreement.
- Earlier response, CNS and safety observations belong to IDeate-PanTumor01 or IDeate-Lung01, not to randomized IDeate-Lung02 efficacy results.
- Reports of the phase 3 interruption do not provide the fatal-ILD count or incidence. Global recruitment interruption, a US partial hold and later reported continuation have different scopes and dates.
- FDA's specific reason for finding the accelerated-approval evidence insufficient remains unresolved in these accounts. Suggested explanations involving available therapy, response durability, safety or design remain attributed interpretations.
- The published design article and registry-based discussion differ on primary endpoint status. The sources do not establish the complete amendment history or whether an earlier filing-supporting analysis will occur.
- Cross-trial comparisons differ by treatment line, geography, eligibility and time. They do not establish comparative efficacy, safety or absence of benefit.
- A published study-design article is available, but no separate protocol document was listed with the registry material. Product-label coverage is incomplete, including no exact I-DXd or amrubicin label, so regulatory and treatment-availability commentary is not a comprehensive label assessment.
- The rebiopsy statement is truncated, and the liquid-biopsy and subtype discussions do not provide a validated I-DXd treatment-selection rule.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-30: current edition

Last checked for new commentary 2026-10-30. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Standard (159 verified statements)
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (20 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/ideate-lung02-nct06203210
- Agents: POST https://www.erudio.com/api/orders with {"report": "ideate-lung02-nct06203210", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=ideate-lung02-06203210

## Cite

Erudio Health. IDeate-Lung02 (NCT06203210): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 30, 2026. https://www.erudio.com/reports/ideate-lung02-nct06203210

## Machine access

- JSON: https://www.erudio.com/reports/ideate-lung02-nct06203210.json
- Markdown: https://www.erudio.com/reports/ideate-lung02-nct06203210.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "ideate-lung02-06203210"}`